Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
Tate M, Illingworth CJR, MacGregor G, Cunningham L, Divers L, McCartney E, Paterson L, Kelly C, Shaw A, Perkins JS, Silva V, Holland P, Dalton C, Carmichael S, Douglas E, Surtees P, Scott JT, Berry C, Vattipally S, Da Silva Filipe A, Tong L, Gunson R; GETAFIX trial co-investigators; McInnes IB, Jones R, Thomson E, Blyth KG.
Tate M, et al. Among authors: tong l.
Antimicrob Agents Chemother. 2025 Jun 24:e0005425. doi: 10.1128/aac.00054-25. Online ahead of print.
Antimicrob Agents Chemother. 2025.
PMID: 40552814